stockrow
Friday 6 November 2026
Export TMCI’s income statement to Excel — free account
Treace Medical Concepts, Inc.
TMCI Healthcare Medical Devices
Treace Medical Concepts, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $212.7 million, up 1.59% from fiscal 2024.
- Revenue
- −3.91%
- EPS
- +26.9%
- Free cash flow
- +54.4%
- Total debt
- +5.11%
Quarter to September 2026, against a year earlier
3.95
0.23
−5.50%
Follow TMCI
Alert me
| Sep '26 From the 10-Q filed 6 Nov | Jun '26 | Mar '26 | Dec '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 |
+8 more quarters Free account |
P/S ratio |
1.43 | 1.26 | 0.42 | 0.73 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(89.30) | (55.11) | 11.96 | (19.31) | |
P/B ratio |
4.72 | 3.82 | 1.12 | 1.77 | |
Price to Tangible BV |
6.85 | 5.36 | 1.51 | 2.30 | |
EV/Sales |
1.52 | 1.32 | 0.45 | 0.77 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
(35.35) | (18.60) | (7.14) | (10.27) | |
EV/FCF |
(16.63) | (10.82) | (3.56) | (5.56) | |
Quick Ratio |
1.52 | 1.79 | 2.38 | 2.95 | |
Current Ratio |
2.58 | 2.90 | 3.58 | 4.31 | |
Net Debt/EBITDA |
0.00 | (0.81) | (0.25) | (2.37) | |
Debt/Assets |
31.38% | 30.95% | 30.32% | 29.17% | |
Debt/Equity |
0.91 | 0.83 | 0.72 | 0.64 | |
Asset Turnover |
1.08 | 1.06 | 1.06 | 1.04 | |
Operating CF/Net income |
0.26 | 0.30 | (0.40) | 0.85 | |
Capex/Depreciation |
0.00 | (1.03) | (2.63) | (0.83) | |
Interest Coverage |
(7.28) | (9.58) | (10.93) | (4.39) | |
Research and Development Expense of Revenue |
9.31% | 9.64% | 9.79% | 7.26% | |
Selling, General and Administrative Expense of Revenue |
94.07% | 101.79% | 105.83% | 82.82% | |
Intangible Assets out of Total Assets |
0.11 | 0.11 | 0.11 | 0.10 | |
Share Based Compensation of Revenue |
14.36% | 14.24% | 17.02% | 12.08% | |
Graham Net Nets |
0.00 | 0.03 | 0.19 | 0.19 | |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
(19.37%) | (23.37%) | (72.39%) | (38.37%) | |
Free Cash Flow Yield |
(6.39%) | (9.67%) | (30.00%) | (19.02%) | |
Revenue per Share |
0.74 | 0.70 | 0.73 | 0.99 | |
Operating CF per Share |
(0.05) | (0.07) | 0.11 | (0.13) | |
Capex per Share |
(0.03) | (0.03) | (0.05) | (0.04) | |
Free Cash Flow per Share |
(0.08) | (0.11) | 0.06 | (0.16) | |
Cash per Share |
0.61 | 0.70 | 0.80 | 0.76 | |
Shareholders Equity per Share |
0.94 | 1.04 | 1.20 | 1.38 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
0.94 | 1.04 | 1.20 | 1.38 | |
Free Cash Flow |
(5.43) | (6.90) | 4.18 | (10.42) | |
Working Capital |
72.61 | 78.96 | 88.98 | 101.42 | |
Capital Expenditures |
(2.17) | (2.20) | (3.06) | (2.40) | |
Net Current Asset Value |
1.03 | 7.14 | 16.56 | 28.81 | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.05 | 0.05 | 0.06 | 0.04 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
31.59 | 29.53 | 30.73 | 41.48 | |
Average Payables |
15.19 | 18.01 | 13.38 | 8.62 | |
Average Inventory |
41.86 | 40.97 | 37.15 | 37.64 | |
Average Assets |
187.95 | 193.75 | 194.97 | 203.84 | |
Average Common Equity |
75.42 | 82.68 | 91.27 | 100.11 |
Columns are period end dates · fundamentals updated 6 Nov 2026